These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

135 related items for PubMed ID: 12538811

  • 1. Assessing safety and efficacy of directed P-glycoprotein inhibition to improve the pharmacokinetic properties of saquinavir coadministered with ritonavir.
    Huisman MT, Smit JW, Wiltshire HR, Beijnen JH, Schinkel AH.
    J Pharmacol Exp Ther; 2003 Feb; 304(2):596-602. PubMed ID: 12538811
    [Abstract] [Full Text] [Related]

  • 2. P-glycoprotein limits oral availability, brain, and fetal penetration of saquinavir even with high doses of ritonavir.
    Huisman MT, Smit JW, Wiltshire HR, Hoetelmans RM, Beijnen JH, Schinkel AH.
    Mol Pharmacol; 2001 Apr; 59(4):806-13. PubMed ID: 11259625
    [Abstract] [Full Text] [Related]

  • 3. P-glycoprotein-mediated active efflux of the anti-HIV1 nucleoside abacavir limits cellular accumulation and brain distribution.
    Shaik N, Giri N, Pan G, Elmquist WF.
    Drug Metab Dispos; 2007 Nov; 35(11):2076-85. PubMed ID: 17709369
    [Abstract] [Full Text] [Related]

  • 4. Increased oral bioavailability of topotecan in combination with the breast cancer resistance protein and P-glycoprotein inhibitor GF120918.
    Kruijtzer CM, Beijnen JH, Rosing H, ten Bokkel Huinink WW, Schot M, Jewell RC, Paul EM, Schellens JH.
    J Clin Oncol; 2002 Jul 01; 20(13):2943-50. PubMed ID: 12089223
    [Abstract] [Full Text] [Related]

  • 5. Effect of saquinavir/ritonavir on P-glycoprotein activity in healthy volunteers using digoxin as a probe.
    Schmitt C, Kaeser B, Riek M, Bech N, Kreuzer C.
    Int J Clin Pharmacol Ther; 2010 Mar 01; 48(3):192-9. PubMed ID: 20197013
    [Abstract] [Full Text] [Related]

  • 6. P-glycoprotein and breast cancer resistance protein influence brain distribution of dasatinib.
    Chen Y, Agarwal S, Shaik NM, Chen C, Yang Z, Elmquist WF.
    J Pharmacol Exp Ther; 2009 Sep 01; 330(3):956-63. PubMed ID: 19491323
    [Abstract] [Full Text] [Related]

  • 7. P-glycoprotein restricts the penetration of oseltamivir across the blood-brain barrier.
    Ose A, Kusuhara H, Yamatsugu K, Kanai M, Shibasaki M, Fujita T, Yamamoto A, Sugiyama Y.
    Drug Metab Dispos; 2008 Feb 01; 36(2):427-34. PubMed ID: 18039806
    [Abstract] [Full Text] [Related]

  • 8. N-(4-[2-(1,2,3,4-tetrahydro-6,7-dimethoxy-2-isoquinolinyl)ethyl]-phenyl)-9,10-dihydro-5-methoxy-9-oxo-4-acridine carboxamide (GF120918) as a chemical ATP-binding cassette transporter family G member 2 (Abcg2) knockout model to study nitrofurantoin transfer into milk.
    Wang L, Leggas M, Goswami M, Empey PE, McNamara PJ.
    Drug Metab Dispos; 2008 Dec 01; 36(12):2591-6. PubMed ID: 18799806
    [Abstract] [Full Text] [Related]

  • 9. Flavonoids chrysin and benzoflavone, potent breast cancer resistance protein inhibitors, have no significant effect on topotecan pharmacokinetics in rats or mdr1a/1b (-/-) mice.
    Zhang S, Wang X, Sagawa K, Morris ME.
    Drug Metab Dispos; 2005 Mar 01; 33(3):341-8. PubMed ID: 15608138
    [Abstract] [Full Text] [Related]

  • 10. Effects of a P-glycoprotein inhibitor on brain and plasma concentrations of anti-human immunodeficiency virus drugs administered in combination in rats.
    Savolainen J, Edwards JE, Morgan ME, McNamara PJ, Anderson BD.
    Drug Metab Dispos; 2002 May 01; 30(5):479-82. PubMed ID: 11950774
    [Abstract] [Full Text] [Related]

  • 11. Increased oral availability and brain accumulation of the ALK inhibitor crizotinib by coadministration of the P-glycoprotein (ABCB1) and breast cancer resistance protein (ABCG2) inhibitor elacridar.
    Tang SC, Nguyen LN, Sparidans RW, Wagenaar E, Beijnen JH, Schinkel AH.
    Int J Cancer; 2014 Mar 15; 134(6):1484-94. PubMed ID: 24037730
    [Abstract] [Full Text] [Related]

  • 12. Characterization of phosphine complexes of technetium(III) as transport substrates of the multidrug resistance P-glycoprotein and functional markers of P-glycoprotein at the blood-brain barrier.
    Luker GD, Rao VV, Crankshaw CL, Dahlheimer J, Piwnica-Worms D.
    Biochemistry; 1997 Nov 18; 36(46):14218-27. PubMed ID: 9369495
    [Abstract] [Full Text] [Related]

  • 13. Influence of atazanavir 200 mg on the intracellular and plasma pharmacokinetics of saquinavir and ritonavir 1600/100 mg administered once daily in HIV-infected patients.
    Ford J, Boffito M, Maitland D, Hill A, Back D, Khoo S, Nelson M, Moyle G, Gazzard B, Pozniak A.
    J Antimicrob Chemother; 2006 Nov 18; 58(5):1009-16. PubMed ID: 16984898
    [Abstract] [Full Text] [Related]

  • 14. Synthesis and in vivo evaluation of ¹⁸F-fluoroethyl GF120918 and XR9576 as positron emission tomography probes for assessing the function of drug efflux transporters.
    Kawamura K, Yamasaki T, Konno F, Yui J, Hatori A, Yanamoto K, Wakizaka H, Ogawa M, Yoshida Y, Nengaki N, Fukumura T, Zhang MR.
    Bioorg Med Chem; 2011 Jan 15; 19(2):861-70. PubMed ID: 21185730
    [Abstract] [Full Text] [Related]

  • 15. Role of breast cancer resistance protein in the bioavailability and fetal penetration of topotecan.
    Jonker JW, Smit JW, Brinkhuis RF, Maliepaard M, Beijnen JH, Schellens JH, Schinkel AH.
    J Natl Cancer Inst; 2000 Oct 18; 92(20):1651-6. PubMed ID: 11036110
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. The effect of Bcrp1 (Abcg2) on the in vivo pharmacokinetics and brain penetration of imatinib mesylate (Gleevec): implications for the use of breast cancer resistance protein and P-glycoprotein inhibitors to enable the brain penetration of imatinib in patients.
    Breedveld P, Pluim D, Cipriani G, Wielinga P, van Tellingen O, Schinkel AH, Schellens JH.
    Cancer Res; 2005 Apr 01; 65(7):2577-82. PubMed ID: 15805252
    [Abstract] [Full Text] [Related]

  • 18. Multidrug resistance protein 2 (MRP2) transports HIV protease inhibitors, and transport can be enhanced by other drugs.
    Huisman MT, Smit JW, Crommentuyn KM, Zelcer N, Wiltshire HR, Beijnen JH, Schinkel AH.
    AIDS; 2002 Nov 22; 16(17):2295-301. PubMed ID: 12441801
    [Abstract] [Full Text] [Related]

  • 19. Preclinical pharmacokinetic properties of the P-glycoprotein inhibitor GF120918A (HCl salt of GF120918, 9,10-dihydro-5-methoxy-9-oxo-N-[4-[2-(1,2,3,4-tetrahydro-6,7-dimethoxy-2-isoquinolinyl)ethyl]phenyl]-4-acridine-carboxamide) in the mouse, rat, dog, and monkey.
    Ward KW, Azzarano LM.
    J Pharmacol Exp Ther; 2004 Aug 22; 310(2):703-9. PubMed ID: 15056727
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.